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Abstract: Rheumatoid arthritis (RA) is an autoimmune disease affecting approximately 1–2% of the
world population. In addition to the first discovered serologic markers for RA, the rheumatoid factors
(RFs), anti-citrullinated protein antibodies (ACPAs) are even more specific for the disease compared
to RFs and are found in 70–80% of RA patient sera. RA etiopathogenesis still needs to be elucidated,
as different factors are proposed to be involved, such as Epstein–Barr virus infection. Hence, under-
standing the interaction between ACPAs and their citrullinated peptide targets is relevant for a better
knowledge of RA pathophysiology and for diagnostic purposes. In this study, a cohort of RA sera,
healthy control sera and multiple sclerosis sera were screened for reactivity to a variety of citrullinated
peptides originating from α-enolase, pro-filaggrin, proteoglycan and Epstein–Barr nuclear antigen-2
by enzyme-linked immunosorbent assay. ACPA reactivity to citrullinated α-enolase peptides was
found to depend on peptide length and peptide conformation, favouring cyclic (disulfide bond)
conformations for long peptides and linear peptides for truncated ones. Additional investigations
about the optimal peptide conformation for ACPA detection, employing pro-filaggrin and EBNA-2
peptides, confirmed these findings, indicating a positive effect of cyclization of longer peptides of
approximately 20 amino acids. Moreover, screening of the citrullinated peptides confirmed that
ACPAs can be divided into two groups based on their reactivity. Approximately 90% of RA sera
recognize several peptide targets, being defined as cross-reactive or overlapping reactivities, and
whose reactivity to the citrullinated peptide is considered primarily to be backbone-dependent. In
contrast, approximately 10% recognize a single target and are defined as nonoverlapping, primarily
depending on the specific amino acid side-chains in the epitope for a stable interaction. Collectively,
this study contributed to characterize epitope composition and structure for optimal ACPA reactivity
and to obtain further knowledge about the cross-reactive nature of ACPAs.
Keywords: anti-citrullinated protein antibodies; citrullinated peptides; epitopes; rheumatoid arthritis
1. Introduction
RA is a systemic and chronic autoimmune disease with a worldwide prevalence of
approximately 5 per 1000 adults, affecting women two to three times more often than
men. RA disease onset may occur at any age; however, the peak incidence is in the sixth
decade [1–3]. RA is characterized by infiltration of monocytes, B cells and T cells in
the synovial membrane in joints and ultimately cartilage degradation and erosion of the
underlying bone [2]. In addition to joint damage, some systemic features are associated
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with RA, for instance pulmonary, cardiovascular, psychological, and skeletal disorders [4,5].
Hence, RA has increased morbidity and mortality rates when left untreated [1,6].
RA is diagnosed according to EULAR/ACR classification criteria revised in 2010
which, along with clinical disease manifestations, comprise serological biomarkers such
as anti-citrullinated protein antibodies (ACPA) [7]. ACPAs are detected in 70–80% of
RA patients and in approximately 1–2% of the healthy population. Moreover, they have
been reported to be present up to 14 years before the manifestation of clinical symptoms,
making ACPAs good biomarkers for RA [8,9]. Ultimately, it has been reported that ACPA-
positive RA patients experience increased joint damage and low remission rates, indicating
that these individuals have more severe disease courses compared to ACPA-negative
RA patients [10]. The occurrence of ACPA-positive RA is related to genetic risk factors
that predispose for RA, for instance, protein tyrosine phosphatase nonreceptor type-22
(PTPN22) and MHC class II alleles [11–14].
ACPAs recognize the nonstandard amino acid citrulline, a nongenetically encoded
amino acid. Citrullination is the result of a post-translational modification, where the
positively charged guanidino group of Arg is substituted by the neutral ureido group.
Ultimately, this modification may lead to structural unfolding of the citrullinated pro-
tein [15,16]. Citrullination is catalyzed by Peptidyl Arginine Deiminase (PAD) enzymes,
which are calcium-dependent metalloenzymes [17].
ACPAs are typically detected with assays, which exploit enzyme-linked immunosor-
bent assay (ELISA) methods and synthetic citrullinated peptides [18–22]. The first genera-
tion of assays was based on a synthetic linear citrullinated peptide derived from human
filaggrin [19]. In order to improve assay sensitivity, the linear peptide was replaced by a
cyclic version (Cyclic Citrullinated Peptide, CCP, containing a disulfide bond), as the cyclic
peptide yielded higher sensitivity and specificity compared to the linear version. This assay
is also referred to as CCP1 [20]. Screening of peptide libraries has led to the selection of
other antigens and generation of second and third generations of CCP assays [18]. While
the previously mentioned assays only detect IgG ACPAs, the CCP3.1 detects both IgG
and IgA isotypes. Despite this, the golden standard for ACPAs detection is the CCP2
assay [18,22].
In the commercial ACPA assays, different citrullinated peptides are employed, which
is in accordance with the cross-reactive nature of ACPAs. ACPAs are able to recognize
several citrullinated targets, preferably containing a Cit–Gly motif [19,21,23–27]. Besides
a critical Cit–Gly motif, charged amino acids in the C-terminal have been proposed to be
essential for a stable interaction between ACPAs and citrullinated peptide targets [23]. The
amino acids surrounding citrulline have been analyzed in several studies, which revealed
that substitutions in positions -x-x-Cit-Gly-x- do not influence antibody reactivity. This find-
ing demonstrates the crucial role of the Cit–Gly motif for a stable antibody–antigen interac-
tion, even though sometimes other amino acids besides Gly are also tolerated [23,24,26–28].
Examples of ACPA targets that have been reported are collagen, fibrinogen, α-enolase,
vimentin, pro-filaggrin, Epstein–Barr nuclear antigen (EBNA)-1, and EBNA-2 [21,22,25].
It has been proposed that ACPAs can be divided into two groups, based on their ability
to interact with citrullinated peptides [16,17], one group that appears to recognize a large
variety of citrullinated targets and another group that recognizes a very limited number of
citrullinated peptides [29]. The first group of ACPAs, also referred to as “overlapping” or
“cross-reactive” antibodies, is primarily backbone-dependent, whereas the second group,
also referred to as “nonoverlapping” or “epitope-specific”, depends on the specific amino
acid side-chains of the epitope to establish a stable antibody–antigen interaction [16].
On this basis, we analyzed the interactions between citrullinated targets and ACPAs in
order to obtain further knowledge about ACPAs, which is important for the improvement
of diagnostic tools, and to elucidate their role in the pathogenesis of RA. Citrullinated
α-enolase peptides were used as a point of origin to characterize epitope composition and
structure for optimal antibody reactivity and the overlapping and nonoverlapping ACPA
reactivities.
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2. Materials and Methods
2.1. Reagents
Alkaline phosphatase (AP)-conjugated goat-anti-human IgG, streptavidin and AP sub-
strate tablets (para-nitrophenylphosphate (pNPP)) were from Sigma Aldrich (St. Louis, MO,
USA). Tris-Tween-NaCl (TTN, 0.3 M NaCl, 20 mM Tris, 0.01% Tween 20, pH 7.5), carbonate
buffer (0.05 M sodium carbonate, pH 9.6) and AP substrate buffer (1 M ethanolamine,
0.5 mM MgCl2, pH 9.8), were from Statens Serum Institut (Copenhagen, Denmark). Syn-
thetic peptides purchased were from Schäfer-N (Lyngby, Denmark) (Table 1) and were
generated on TentaGel resin using standard Fmoc-based solid-phase peptide synthesis.
The peptides were synthesized as peptide acids.











Fibronectin Fibronectin L DHEGTHSTK-Cit-GHAKSRPVRD(K(B))
Proteoglycan Proteoglycan L B-PQASVPLRLT-Cit-GSRAPISRAQ
Pro-filaggrin Pro-filaggrin C HQCHQEST-Cit-GRSRGRCGRSGS(K(B))
Pro-filaggrin L HQSHQEST-Cit-GRSRGRSGRSGS(K(B))
Epstein–Barr virus EBNA-2-L GQGRGRWRG-Cit-GRSKGRGRMH(K(B))
Nuclear antigen 2 EBNA-2-C GQGRCGRWRG-Cit-GRSKGRGCRMH(K(B))
2.2. Patient Material
RA serum samples (n = 28) and healthy donor (n = 28) serum samples (referred to
as healthy control (HC)) were provided by Statens Serum Institut Biobank (Copenhagen,
Denmark) (n = 28), which routinely analyzes patient sera for diagnostic purposes. The
samples were tested anonymously, therefore not requiring ethical consent.
Ten multiple sclerosis serum samples from the Multiple Sclerosis Clinic, Department
of Neurology, Rigshospitalet Glostrup (Glostrup, Denmark) were used as disease controls.
The samples were tested anonymously, therefore not requiring ethical consent.
2.3. Detection of Antibodies by Enzyme-Linked Immunosorbent Assay and Streptavidin-Capture
Enzyme-Linked Immunosorbent Assay
Microtiter plates were coated with 1 µg/mL free peptide in carbonate buffer and
incubated overnight at room temperature (RT) on a shaking table (ST). The wells were
rinsed with TTN for 3 × 1 min and blocked with TTN for 30 min. Sera were diluted (1:200)
in TTN, added to each well, and then incubated for 1 h (h) at RT on a ST. After washing
with TTN buffer, AP-conjugated goat-anti-human IgG diluted in TTN (1:1000) was added
to each well and incubated for 1h at RT on a ST. Finally, pNPP-containing AP substrate
buffer (1 mg/mL) was added to each well and AP activity was determined by measuring
the absorbance at 405 nm with background subtraction at 650 nm.
Alternatively, microtiter plates were precoated with 1 µg/mL streptavidin in carbonate
buffer and incubated overnight at 4 ◦C. Biotinylated peptides (diluted to 1 µg/mL in
carbonate buffer) were added to each well and incubated for 2h at RT on a ST. The following
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steps in the experiment were carried out as mentioned above. All samples were tested in
duplicates.
Based on preliminary screening, absorbances of all the results were normalized to a
positive RA control pool (n = 28) and a peptide-specific cutoff was introduced, tolerating
a nonspecific reactivity of 5% and an intra-assay variation of 15%. Readings above the
cutoff were regarded as positive, whereas samples below the cutoff were regarded as being
negative. Inter-assay variations below 15% were acceptable.
2.4. Statistics
Statistical analyses and plots were generated using GraphPad Prism 9.0 software. The
values obtained in the experiments were compared further by using Student’s t-test.
3. Results
3.1. Reactivity of Rheumatoid Arthritis Sera to α-Enolase Peptides
Various citrullinated protein targets have been identified in RA, such as α-enolase,
pro-filaggrin, proteoglycan, and fibronectin [30,31]. In order to further characterize the re-
activity of ACPA to citrullinated peptides, RA patient sera (n = 28), HC sera (n = 28) and MS
sera (n = 10) were tested for reactivity to a citrullinated α-enolase peptide (KIHARCEIFDS-
Cit-GNPTVEC) by ELISA.
As seen in Figure 1, elevated antibody reactivity was found to the citrullinated peptides
compared to the Arg-containing control peptide (p = 0.0073 for the cyclic and p = 0.0003
for the linear). No significant difference in antibody reactivity was found between the
cyclic and the linear α-enolase peptides (p = 0.2647). Approximately 40% of the RA sera
recognized the α-enolase peptides, and reacted significantly to the linear and the cyclic
peptide compared to the control peptide (p < 0.0001). None of HC sera or MS sera reacted
to the citrullinated α-enolase peptides, confirming that ACPA reactivity to the α-enolase
peptides was specific for RA.
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Figure 1. Reactivity of rheumatoid arthritis (RA), healthy control (HC) and multiple sclerosis (MS) 
sera to α-enolase peptides (KIHARCEIFDS-Cit-GNPTVEC) analysed by traditional ELISA. A linear 
Arg-containing peptide (KIHARCEIFDS-R-GNPTVEC) was used as negative control. HC and MS 
sera were used as controls. A.U. were defined as absorbances normalized relative to a positive RA 
control pool. p values less than 0.001 are shown as ***. 
Figure 1. Reactivity of rheumatoid arthritis (RA), healthy control (HC) and multiple sclerosis (MS)
sera to α-enolase peptides (KIHARCEIFDS-Cit-GNPTVEC) analysed by traditional ELISA. A linear
Arg-containing peptide (KIHARCEIFDS-R-GNPTVEC) was used as negative control. HC and MS
sera w re used as controls. A.U. w re defined as absorbances normalized relative to a positive RA
control p ol. p values less than .001 are shown as **.
3.2. Reactivity of Rheumatoid Arthritis Sera to Truncated Linear and Cyclic α-Enolase Peptides
Previous studies describing RA sera reactivity to citrullinated pro-filaggrin peptides
indicated that ACPA reactivity is dependent on peptide length and conformation [23]. To
determine whether this relates to α-enolase peptides as well, RA sera that were positive for
reactivity to α-enolase in the preliminary screening (n = 12) were tested for reactivity to
cyclic and linear truncated α-enolase peptides by ELISA.
As seen in Figure 2, RA sera recognized all of the linear peptides independent of their
length. Sensitivities of approximately 90% were found for all of the linear peptides. In
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contrast, specific ACPA reactivity was primarily found to the cyclic peptides C-19-Cit and
C-10-Cit, obtaining sensitivities of approximately 90% as well. These findings indicate that
the peptide conformation affects the antibody reactivity and that it is essential for peptide
presentation. Additionally, no specific reactivity was found when screening HC sera. These
findings are in accordance with the literature, describing that ACPA reactivity to 19-mer
linear and cyclic pro-filaggrin peptides yields similar reactivity, whereas ACPA reactivity
to the linear citrullinated peptides is favoured for smaller peptides (<12 amino acids), when
compared to the cyclic peptides [23].
Antibodies 2021, 10, x FOR PEER REVIEW 5 of 12 
 
 
3.2. Reactivity of Rheumatoid Arthritis Sera to Truncated Linear and Cyclic α-Enolase Peptides 
Previous studies describing RA sera reactivity to citrullinated pro-filaggrin peptides 
indicated that ACPA reactivity is dependent on peptide length and conformation [23]. To 
determine whether this relates to α-enolase peptides as well, RA sera that were positive 
for reactivity to α-enolase in the preliminary screening (n = 12) were tested for reactivity 
to cyclic and linear truncated α-enolase peptides by ELISA. 
As seen in Figure 2, RA sera recognized all of the linear peptides independent of their 
length. Sensitivities of approximately 90% were found for all of the linear peptides. In 
contrast, specific ACPA reactivity was primarily found to the cyclic peptides C-19-Cit and 
C-10-Cit, obtaining sensitivities of approximately 90% as well. These findings indicate that 
the peptide confor ation affects the antibody reactivity and that it is essential for peptide 
presentation. dditionally, no specific reactivity was found when screening HC sera. 
These findings are in accordance with the literature, describing that ACPA reactivity to 
19-mer linear and cyclic pro-filaggrin pepti es yields similar reactivity, whereas ACPA 
reactivity to the line r citrullinated peptides is favoured for smaller peptides (<12 amino 
acids), when compared to the cyclic peptides [23]. 
 
Figure 2. Reactivity of rheumatoid arthritis (RA) sera and healthy control (HC) sera samples to trun-
cated linear and cyclic citrullinated α-enolase peptides analysed in ELISA. Peptides are plotted from 
left to right with decreasing length. An Arg-containing peptide was used as control (KIHARCEI-
FDSRGNPTVEC). (a) Reactivity of RA sera to linear peptides. (b) Reactivity of HC sera to linear 
peptides. (c) Reactivity of RA sera to cyclic peptides. (d) Reactivity of HC sera to cyclic peptides. 
A.U. were defined as absorbances normalized relative to a positive RA control pool. 
3.3. Overlapping Reactivities of Anti-Citrullinated Protein Antibody Responses 
As presented, approximately 40% of the RA sera reacted with the α-enolase peptides. 
To determine whether the ACPA reactivities were specific for the α-enolase peptide, all 
RA sera (n = 28) and HC sera (n = 28) were tested for reactivity to various citrullinated 
peptides in ELISA. Peptides from pro-filaggrin, proteoglycan, fibronectin, and EBNA-2 
were tested for antibody reactivity. 
As shown in Figure 3, significant RA antibody reactivity was found to the citrulli-
nated pro-filaggrin (p = 0.0119), proteoglycan (p = 0.0004), fibronectin (p = 0.0459) and 
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A.U. were defined as absorbances normalized relative to a positive RA control pool.
3.3. Overlapping Reactivities of Anti-Citru linated Protein ntibody espo ses
s presented, approxi atel 40 of the RA sera reacted with the α-enolase peptides.
T t i e et er t e i iti r ifi ti , ll
R sera (n 28) and sera ( 28) ere t t f ti it t i it lli t
peptides in I . ti es fr r -fil ri , r t l ca , fi r ecti , -
ere teste for a ti o reacti it .
s sho n in Figure 3, significant RA antibody reactivity was found to the citrullinated
pro-filaggrin (p = 0.0119), proteoglycan (p = 0.0004), fibronectin (p = 0.0459) and EBNA-2
(p < 0.0001) peptides compared to the HC. The proteoglycan and EBNA-2 peptides obtained
the highest sensitivities of 50% and 68%, respectively. One HC serum showed low reactivity
to EBNA-2 L (Figure 3b).
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Thorough analysis of the reactivities of the RA sera showed that approximately 14%
of the RA sera samples recognized a l 4 peptides, whereas 18 reacted to 3 peptides. Note
that approxi ately 54 of the samples recognized 1 or 2 peptides, whereas 14 of the RA
cohort did not show reactivity to any of the peptides (Ta le , fi t l ).
Table 2. eacti iti t citrul inated peptides originating from pro-filaggrin, proteo-
glycan, fibronectin and EBNA-2.
T Cohort α-Enolase PositiveRA Cohort
α-Enolase Negative
RA Cohort
n 8 12 16
4 reactive peptides 4 (14.3%) 2 (16.7%) 2 (12.5%)
tive peptides .9%) 4 (3 .3%) 1 (6.3%)
2 reactive peptides 6 (21.4%) 3 (25.0%) 3 (18.8%)
1 reactive peptide 9 (32.1%) 2 (16.7%) 7 (43.8%)
0 reactive peptides 4 (14.3%) 1 (8.3%) 3 (18.8%)
Of the 9 RA sera that only reacted with 1 peptide (Table 2, first colu n), 22% reacted
with the proteoglycan peptide (n = 2), 22% with the fibronectin peptide (n = 2) and 56%
(n = 5) with EBNA-2 peptide.
When dividing the complete RA cohort into α-enolase-positive and -negative sera, it
was observed that the RA samples in the α-enolase-positive cohort were prone to have
a higher degree of overlapping antibody reactivities compared to the α-enolase-negative
cohort. For instance, 50% of the RA sera in the α-enolase-positive cohort recognized 3
or 4 peptides compared to 19% in the α-enolase-negative cohort. Similarly, 42% of the
α-enolase-positive cohort recognized 1 or 2 peptides compared to 63% for the α-enolase-
negative cohort.
When examining the reactivity of the 3 cohorts (complete cohort, α-enolase-positive
cohort, α-enolase-negative cohort) to the three most reactive peptides, pro-filaggrin, proteo-
glycan, and EBNA-2 L, similar results were obtained. As presented in Figure 4, significant
overlapping reactivities were found between the 3 cohorts.
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Sera that only reacted to one peptide primarily recognized EBNA-2, as described
earlier. Moreover, the most significant overlap in antibody reactivity was found between
EBNA-2 and proteoglycan (Figure 4a,b), which is in accordance with the fact that these
peptides obtained the highest sensitivities, as presented in Figure 3.
3.4. Reactivity of RA Sera to Linear and Cyclic Peptide Versions. Is the Effect of Cyclization on
Antibody Sensitivity General?
Previous findings indicated that the cyclic version of the α-enolase peptide had a
higher sensitivity, although not statistically significant when compared to the linear peptide.
To determine whether this effect is general or peptide-specific, RA reactivity to linear and
cyclic citrullinated pro-filag ri and EBNA-2 pe tides were tested in ELISA.
Figure 5 illustrates the reactivity of RA and HC s ra to the linear and cyclic Pro-
filaggrin and EBNA-2 peptide. ACPA reactivity to the cit ullinated peptides was signifi-
cantly elevated compared to the HCs (p = 0.0044 for EBNA-2 L, p < 0.0001 for EBNA-2 C,
p = 0.0028 for pro-filaggrin L, p < .0001 for pro filaggrin C).
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Figure 5. Reactivity of rheumatoid arthritis (RA) samples and healthy control (HC) samples to pro-filaggrin (25 RA and 
25 HC samples) and EBNA-2 (28 RA and 28 HC samples) peptides in their linear and cyclic conformation. (a) Reactivity 
of RA and HC sera to citrullinated cyclic and linear EBNA-2 peptides. (b) Reactivity of RA and HC sera to citrullinated 
cyclic and linear pro-filaggrin peptides. A.U. were defined as absorbances normalized relative to a positive RA control 
pool. *** p < 0.001, ** p < 0.01, * p < 0.05. 
Moreover, cyclization was observed to increase assay sensitivity, as the cyclic EBNA-
2 and pro-filaggrin peptides had higher sensitivitities compared to the linear peptides (p 
= 0.0331), 67% and 44% of the RA sera reacted to the cyclic and linear EBNA-2 peptide, 
respectively, whereas 68% and 44% of the RA sera reacted to the cyclic and linear pro-
filaggrin peptides, respectively. No statistically significant difference in antibody reactiv-
ity to the linear and cyclic pro-filaggrin peptides was found, although the antibody reac-
tivity to the cyclic version was elevated (Figure 5b). 
Collectively, these findings indicate that peptide conformation and peptide length 
affect antibody reactivity. 
4. Discussion 
In the present study, we analysed the reactivity of peptide-specific ACPAs to citrul-
linated epitopes and confirmed that factors such as peptide length and conformation no-
tably influence antigen presentation. 
The sensitivity of the full-length α-enolase peptide was determined to be approxi-
mately 44%, which is supported by earlier findings described in the literature [32]. ACPA 
reactivity to α-enolase was originally described by Lundberg et al., who showed that a 
cyclic peptide obtained the highest antibody reactivity among the human α-enolase and 
Porphyromonas gingivalis enolase peptides tested [32]. Similarly, no reactivity was found 
to the Arg-containing control peptide, confirming that the ACPAs are citrulline-specific 
(Figure 1). In addition to this, MS samples were tested for reactivity to the linear α-enolase 
peptide, as it has been described that citrullinated protein levels are elevated in MS [33], 
however, no reactivity was observed, confirming that ACPA reactivity is specific for RA. 
The above mentioned experiments using α-enolase peptides were conducted in the 
absence of reducing agents, thus the linear peptides may in theory be able to cyclize dur-
ing coating; however, as the effect of cyclization for α-enolase peptides was the same for 
pro-filaggrin and EBNA-2 peptides, where no cysteines were found in the linear peptides, 
we have reason to believe that the α-enolase peptides were found in a linear form during 
coating [23]. 
Screening of the truncated α-enolase peptides showed that all of the linear peptides 
(L-19-Cit, L-14-Cit, L-12-Cit and L-10-Cit) were roughly recognized to the same extent by 
the RA cohort, indicating that the length of the linear peptides is less important compared 
to the cyclic peptides. These findings confirm that the Cit–Gly motif in combination with 
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of RA and HC sera to citrullinated cyclic and line r EBNA-2 peptides. (b) Reactivity of RA and HC sera to citrullinated
cyclic and linear pro-filaggrin peptides. A.U. were defined as absorbances normalized relative to a positive RA control pool.
*** p < 0.001, ** p < 0.01, * p < 0.05.
Moreover, cyclization was observed to increase assay sensitivity, as the cyclic EBNA-
2 and pro-filaggrin peptides had higher sensitivitities compared to the linear peptides
(p = 0.0331), 67% and 44% of the RA sera reacted to the cyclic and linear EBNA-2 peptide,
respectively, whereas 68% and 44% of the RA sera reacted to the cyclic and linear pro-
filaggrin peptides, respectively. No statistically significant difference in antibody reactivity
to the linear and cyclic pro-filaggrin peptides was found, although the antibody reactivity
to the cyclic version was elevated (Figure 5b).
C llectively, the e findings indicate that peptide conformation and peptide length
affect antibody reactivity.
4. Discussion
In the present study, we analysed the reactivity of peptide-specific ACPAs to citrulli-
nated epitopes and confirmed that factors such as peptide length and conformation notably
influence antigen presentation.
The sensitivity of the full-length α-enolase peptide was determined to be approxi-
mately 44%, which is supported by earlier findings described in the literature [32]. ACPA
reactivity to α-enolase was originally described by Lundberg et al., who showed that a
cyclic peptide obtained the highest antibody reactivity among the human α-enolase and
Porphyromonas gingivalis enolase peptides tested [32]. Similarly, no reactivity was found
to the Arg-containing control peptide, confirming that the ACPAs are citrulline-specific
(Figure 1). In addition to this, MS samples were tested for reactivity to the linear α-enolase
peptide, as it has been described that citrullinated protein levels are elevated in MS [33],
however, no reactivity was observed, confirming that ACPA reactivity is specific for RA.
The above mentioned experiments using α-enolase peptides were conducted in the
absence of reducing agents, thus the linear peptides may in theory be able to cyclize during
coating; however, as the effect of cyclization for α-enolase peptides was the same for
pro-filaggrin and EBNA-2 peptides, where no cysteines were found in the linear peptides,
we have reason to believe that the α-enolase peptides were found in a linear form during
coating [23].
Screening of the truncated α-enolase peptides showed that all of the linear peptides
(L-19-Cit, L-14-Cit, L-12-Cit and L-10-Cit) were roughly recognized to the same extent by
the RA cohort, indicating that the length of the linear peptides is less important compared
to the cyclic peptides. These findings confirm that the Cit–Gly motif in combination with
a peptide backbone of approximately 10 amino acids, perhaps even shorter, is sufficient
for antibody binding, as previously proposed [23]. In terms of reactivity, L-14-Cit, which
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is the second-longest peptide, showed the highest reactivity. In a study conducted using
pro-filaggrin peptides, it was found that a linear 21-mer peptide and a linear 14-mer
peptide were significantly recognized by ACPAs. Moreover, the 14-mer peptide obtained
the highest sensitivity, which conforms to this study, favouring peptides of approximately
10–14 amino acids [27]. This effect may relate to the peptide structure. Even though a small
number of amino acids are flanking the Cit–Gly motif in the shorter peptides, the peptides
are still able to fold and thus acquire a specific conformation that appears to bind to ACPAs
more efficiently. The exact reason remains to be determined.
Increased sensitivities were obtained for the longest (C-19-Cit) and the shortest (C-10-
Cit) cyclic α-enolase peptides compared to the C-14-Cit and C-12-Cit peptides, indicating
that peptide length and conformation are crucial for peptides containing 12–19 amino acids.
These findings are supported by the literature, where it has been reported that the reduced
number of amino acids in the cyclic structure may constrain the peptide in a more locked
conformation, reducing the flexibility of the peptides and hence negatively influencing the
ACPA reactivity [16]. The fact that the smaller peptide (C-10-Cit) was as sensitive as the
longest peptide (C-19-Cit), and thus more sensitive than the mid-length peptides (C-12-Cit
and C-14-Cit), is intriguing. This interesting reactivity pattern to truncated cyclic peptides
could be further investigated by performing crystallography studies of the ACPA binding
groove. Ultimately, these findings regarding truncated peptides (both linear and cyclic)
confirm that peptide length and conformation are essential for antibody reactivity.
Concerning the aspect of cyclization, it has been reported that peptide cyclization has a
positive effect upon antibody reactivity [14]. Our studies of pro-filaggrin and EBNA-2 cyclic
and linear peptides revealed an evident increase in the antibody reactivity to the cyclic
peptides compared to the linear peptides. These results are consistent with the longest
α-enolase peptides (L-19-Cit and C-19-Cit). Nevertheless, for the α-enolase peptides, the
reactivity to linear peptides did not depend on peptide length, whereas ACPA reactivity to
cyclic peptides was length-dependent. This effect is in direct contrast to earlier findings
using cyclic and linear pro-filaggrin peptides, where ACPA reactivity to both the linear and
the cyclic peptides appeared to be length-dependent [27]. This may in theory be ascribed
to the peptides used, as the pro-filaggrin and EBNA-2 peptides were biotinylated, whereas
the α-enolase peptides had free terminals, hence the absence of biotin may have influenced
the peptide coating. Thus, further analyses are necessary to confirm these results.
When focusing on the peptide sequence, a high degree of homology is found between
pro-filaggrin and EBNA-2 in the C-terminal region, where positively charged and small
amino acids are present (Table 1). The high degree of sequence homology may explain the
similar sensitivities that the peptides yielded, suggesting that peptide sequence influences
antibody reactivity. However, the Proteoglycan Cit peptide sequence does not have ho-
mology in the C-terminal end to pro-filaggrin and EBNA-2 and still yields a sensitivity of
approximately 50%. Since several sequence patterns along with a Cit–Gly motif can be
found among the peptides tested, these observations led to the hypothesis that a struc-
tural homology could be shared by the citrullinated peptides recognized by ACPAs. This
remains to be elaborated.
Screening of the RA and the HC cohorts on a peptide panel, including four citrullinated
peptides from pro-filaggrin, proteoglycan, fibronectin and EBNA-2, revealed a significantly
different reactivity between RA and HC samples (Figure 3). The citrullinated peptides
obtained the following sensitivities: Pro-filaggrin 32%, Fibronectin 36%, Proteoglycan 50%
and EBNA-2 68%. In addition, more than 50% of the RA samples reacted with more than
one peptide of the panel, confirming the ability of ACPAs to bind to several citrullinated
targets. Further investigation analysing the overlapping reactivities of the RA sera within
the peptide panel (Figure 3) showed that approximately 32% reacted with 3 or 4 peptides,
21% with 2 peptides, 14% did not react at all and, lastly, 32% of the cohort only showed
reactivity to one peptide, which in 56% of the cases was the EBNA-2 peptide, suggesting
the presence of EBNA-2-specific ACPAs. The fact that most of the RA samples interacted
with more than one peptide supports the theory of the overlapping reactivity of ACPAs,
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highlighting the central role of the Cit–Gly motif together with the surrounding amino
acids for antigen–antibody binding.
The previous findings led us to compare the ACPA reactivities between the peptide
panel and the α-enolase peptides, dividing them into α-enolase-positive and -negative ones.
As shown in Table 2, within the α-enolase-positive cohort (n = 12), all the RA sera reacted
with EBNA-2 peptide and no monospecific reactivity was detected to pro-filaggrin and pro-
teoglycan peptides. One RA sample of the α-enolase-positive cohort only showed reactivity
to the α-enolase peptide and not to the whole peptide panel, indicating that it was specific
for the side-chains of the α-enolase epitope rather than the actual backbone in combination
with a central Cit–Gly motif. In the α-enolase-negative cohort, more monospecific reactivi-
ties were observed. These findings are in accordance with the literature, which reports that
approximately 15% of the RA sera are monospecific [30]. Additionally, although a small
part of the RA sera reacted with only one citrullinated peptide, these results confirm the
theory of overlapping and nonoverlapping ACPA reactivities. Here, the α-enolase-positive
cohort was regarded to have overlapping ACPAs, which are considered as backbone-
dependent, whereas the α-enolase-negative cohort was accounted to the nonoverlapping
group of ACPAs, which depend on the flanking amino acid side-chains to establish a
stable antigen–antibody interaction [16]. Collectively, the RA sera that were positive for
α-enolase turned out to be more overlapping within the peptide panel compared to the
α-enolase-negative cohort.
5. Conclusions
RA is an autoimmune disease that affects many people and reduces their quality of
life. Thus, early diagnosis of the disease is fundamental to undertake therapy as soon
as possible and to prevent disease progression. One of the most important diagnostic
criteria is the detection of autoantibodies directed to a variety of citrullinated antigens in
the serum of the patient. The origin of these autoantibodies is still unknown, and thus,
gaining knowledge about the epitopes that ACPAs are able to recognize is important in the
development of more sensitive and more specific diagnostic tools and to obtain a better
understanding of the pathophysiological mechanisms. For these purposes and to elucidate
the etiology of RA, interactions between ACPAs and potential candidate (auto)antigens
were analysed.
Regarding the experiments to further investigate the structure and composition of
ACPAs, these results confirm their cross-reactive nature. The analysed RA sera showed a
different reactivity pattern to the citrullinated peptide panel in relation to the α-enolase-
positive and -negative cohorts. This result indicates that ACPAs can be divided into two
categories based on their ability to bind to a wider or a more limited number of citrulli-
nated targets, which, respectively, reflects the peptide backbone and peptide side-chains
dependencies. Especially, the ability of ACPAs to react with various citrullinated targets
can be explained by a similar structure of citrullinated epitopes. Early studies showed that
positively charged and small amino acids in the C-terminal end relative to citrulline yield
high sensitivities. However, not all the peptides tested in this study have these features
but can still interact with ACPAs (Table 1). Therefore, a structural homology, rather than
sequence homology, should be important for ACPA recognition of the citrullinated targets,
and this would, in addition, support the theory that the overlapping group of ACPAs is
backbone-dependent. To obtain a better knowledge of the structure and to find a pattern
that brings together all the citrullinated targets that interact with ACPAs, circular dichroism
analyses could be performed.
Within the peptides tested on the RA cohort, the epitope originating from α-enolase, a
known autoantigen in RA, was confirmed to have a lower sensitivity compared to available
commercial assays and other citrullinated peptides, such as the EBNA-2 peptide, which
was confirmed to be a highly sensitive substrate, even though contribution of EBV infection
to RA onset still needs to be clarified.
Collectively, this study contributes to the understanding of the nature of ACPAs.
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